Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy

 
• By Alaric DeArment
  
Takeda announced positive topline results from the Phase III LATITUDE trials of zasocitinib. • Source: Shutterstock

More from Clinical Trials

More from R&D